NVS
Price
$99.39
Change
+$0.12 (+0.12%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
197.93B
17 days until earnings call
SCLX
Price
$0.44
Change
-$0.00 (-0.00%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
165.55M
Ad is loading...

NVS vs SCLX

Header iconNVS vs SCLX Comparison
Open Charts NVS vs SCLXBanner chart's image
Novartis AG
Price$99.39
Change+$0.12 (+0.12%)
Volume$34.24K
Capitalization197.93B
Scilex Holding
Price$0.44
Change-$0.00 (-0.00%)
Volume$3.1K
Capitalization165.55M
NVS vs SCLX Comparison Chart
Loading...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NVS vs. SCLX commentary
Jan 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVS is a StrongBuy and SCLX is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 15, 2025
Stock price -- (NVS: $99.37 vs. SCLX: $0.45)
Brand notoriety: NVS and SCLX are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: NVS: 152% vs. SCLX: 45%
Market capitalization -- NVS: $197.93B vs. SCLX: $165.55M
NVS [@Pharmaceuticals: Major] is valued at $197.93B. SCLX’s [@Pharmaceuticals: Major] market capitalization is $165.55M. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVS’s FA Score shows that 3 FA rating(s) are green whileSCLX’s FA Score has 0 green FA rating(s).

  • NVS’s FA Score: 3 green, 2 red.
  • SCLX’s FA Score: 0 green, 5 red.
According to our system of comparison, NVS is a better buy in the long-term than SCLX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVS’s TA Score shows that 4 TA indicator(s) are bullish while SCLX’s TA Score has 3 bullish TA indicator(s).

  • NVS’s TA Score: 4 bullish, 5 bearish.
  • SCLX’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, both NVS and SCLX are a bad buy in the short-term.

Price Growth

NVS (@Pharmaceuticals: Major) experienced а +0.39% price change this week, while SCLX (@Pharmaceuticals: Major) price change was -6.41% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.05%. For the same industry, the average monthly price growth was -2.28%, and the average quarterly price growth was -8.52%.

Reported Earning Dates

NVS is expected to report earnings on Apr 29, 2025.

SCLX is expected to report earnings on May 12, 2023.

Industries' Descriptions

@Pharmaceuticals: Major (-2.05% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVS($198B) has a higher market cap than SCLX($166M). SCLX YTD gains are higher at: 3.940 vs. NVS (2.014). NVS has higher annual earnings (EBITDA): 18.3B vs. SCLX (-109.1M). NVS has more cash in the bank: 14B vs. SCLX (3.92M). SCLX has less debt than NVS: SCLX (128M) vs NVS (26.3B). NVS has higher revenues than SCLX: NVS (46.7B) vs SCLX (46.7M).
NVSSCLXNVS / SCLX
Capitalization198B166M119,277%
EBITDA18.3B-109.1M-16,773%
Gain YTD2.0143.94051%
P/E Ratio23.38N/A-
Revenue46.7B46.7M100,000%
Total Cash14B3.92M357,052%
Total Debt26.3B128M20,547%
FUNDAMENTALS RATINGS
NVS: Fundamental Ratings
NVS
OUTLOOK RATING
1..100
12
VALUATION
overvalued / fair valued / undervalued
1..100
13
Undervalued
PROFIT vs RISK RATING
1..100
27
SMR RATING
1..100
23
PRICE GROWTH RATING
1..100
73
P/E GROWTH RATING
1..100
89
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NVSSCLX
RSI
ODDS (%)
Bullish Trend 7 days ago
43%
Bullish Trend 7 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 7 days ago
41%
Bearish Trend 7 days ago
42%
Momentum
ODDS (%)
Bullish Trend 7 days ago
45%
Bearish Trend 7 days ago
41%
MACD
ODDS (%)
Bullish Trend 7 days ago
56%
Bullish Trend 7 days ago
40%
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
48%
Bullish Trend 7 days ago
41%
TrendMonth
ODDS (%)
Bearish Trend 7 days ago
40%
Bearish Trend 7 days ago
83%
Advances
ODDS (%)
Bullish Trend 7 days ago
46%
Bullish Trend 9 days ago
68%
Declines
ODDS (%)
Bearish Trend 13 days ago
46%
Bearish Trend 7 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
39%
N/A
Aroon
ODDS (%)
Bearish Trend 7 days ago
32%
Bearish Trend 7 days ago
88%
View a ticker or compare two or three
Ad is loading...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MYTE7.550.21
+2.86%
MYT Netherlands Parent BV
HOMB27.570.34
+1.25%
Home BancShares
BASE15.970.17
+1.08%
Couchbase
AXON568.68-1.32
-0.23%
Axon Enterprise
IRD1.21-0.21
-14.79%
Opus Genetics Inc

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been loosely correlated with AZN. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then AZN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
+0.19%
AZN - NVS
52%
Loosely correlated
-1.91%
SNY - NVS
40%
Loosely correlated
-0.25%
RHHBY - NVS
37%
Loosely correlated
-0.74%
GSK - NVS
36%
Loosely correlated
-1.18%
JNJ - NVS
34%
Loosely correlated
+1.70%
More

SCLX and

Correlation & Price change

A.I.dvisor tells us that SCLX and AMRN have been poorly correlated (+20% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SCLX and AMRN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCLX
1D Price
Change %
SCLX100%
-2.51%
AMRN - SCLX
20%
Poorly correlated
-6.72%
BIIB - SCLX
10%
Poorly correlated
+0.91%
GRFS - SCLX
8%
Poorly correlated
-0.82%
AZN - SCLX
8%
Poorly correlated
-1.91%
RHHVF - SCLX
8%
Poorly correlated
-1.11%
More